The Kura MD telemedicine platform enables convenient, secure, HIPAA compliant telehealth appointments between physicians and patients through a computer, smart phone or tablet 24 hours a day, seven days a week. Kura MD represents a new standard in telehealth services incorporating electronic medical records (EMR), an interface hub, registration system, verification, billing, claims, video conferencing, and integration of peripheral equipment, practice management and an optional best-in-class health station.
StemExpress fuels regenerative medicine and translational research by supplying human specimens to biomedical researchers around the world. Founded in 2010, StemExpress is the only company of its kind to procure tissues and isolate cells for researchers’ individual needs in its own labs.
ViVita’s patent-pending platform technology—the ViVita Process—removes the immunological barriers in animal-derived tissues, rendering them immune-compatible with human patients. Leveraging this technology, ViVita aims to generate off-the-shelf tissue and organ replacements that avoid long-term medication, repeat transplants, and associated patient deaths.
Juno Biomedical, Inc was founded on a vision that it is possible for modern medicine to treat the root cause of disease. We are driven to do more than treat the symptoms; our mission is to give life back to those who have suffered a loss of function due to neurological damage after a stroke by developing a device that enhances the body’s natural reparative process to reverse the damage. CELLTech™ has been developed under an issued patent. The Juno Biomedical, Inc. team has been working closely with the FDA since 2018 as part of the Early Feasibility Study (EFS) Program. The purpose of the EFS program is to fast-track highly novel devices to the clinic. We are also in the process of working closely with federal funding bodies to support the CELLTech™ feasibility clinical trial.
SynGen Inc. enables regenerative cures through innovative engineering. The company invents and commercializes products that utilize single-use sterile plastic cartridge disposables mated to dedicated, highly automated electromechanical medical devices to isolate and capture stem and progenitor cells from peripheral and umbilical cord blood, bone marrow, and adipose tissue.
Specialty MD is using technology to better connect patients and doctors within the healthcare industry. It consists of a physician directory online, accessible to those looking for health care. The purpose of Specialty MD is to find patients specialty care at the click of a computer screen.
Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We focus in three target markets to serve patients, physicians and partners:
Cellular Therapeutics
Medical/Diagnostic Device Development and Commercialization
Cell Manufacturing and Banking
From the start, our team focused on improving the breastfeeding experience. Initially, we wanted to redesign the breast pump.
When Anna, our co-founder and CEO, interned in Brazil, she learned about different manual breast massage techniques that can help mothers express milk, increase milk supply, and alleviate pain from engorgement. That’s when we realized that we cannot keep putting technology between the mom and the baby. Instead, we need to initiate a breastfeeding culture shift in the United States.
Our goal is to improve the breastfeeding experience by discovering, testing, and teaching evidence-based breast massage techniques to parents and health providers.
Adrastia Biotechnology was founded in 2013 to provide a highly accurate Breast Cancer diagnostic protocol that is easy to administer, non-invasive, will deliver rapid results, and provide women with a personal health history.
Adrastia Biotechnology obtains the urine sample and runs high throughput protein quantification and targeted mRNA/microRNA sequencing to identify a pattern of breast cancer positive or negative as compared to a standard or the woman's own previous pattern. Unlike 100% genomic data, Adrastia's test results are designed to be actionable by the woman's physician and her pattern will be stored in her health record for future reference.
